Lipella presents positive Phase 2a data for LP-310; 0.50mg dose shows stat-sig efficacy in OLP

LIPELLA PHARMACEUTICALS INC.

Statistically significant improvements at 0.50mg dose: IGA from 3.42 to 1.71 (p=0.007), REU from 26.91 to 11.88 (p=0.003).
OLP Symptom Severity Measure dropped from 14.92 to 4.88 (p=0.003); Pain NRS from 6.42 to 2.25 (p=0.003).
No treatment-related serious adverse events, no discontinuations, and no detectable systemic tacrolimus levels.
Data from 0.25mg and 0.50mg cohorts presented at 2025 AAOM/EAOM meeting; final topline data from fully enrolled trial expected Q2 2025.

item 7.01 item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001753926-25-000842
form_type: 8-K
ticker: LIPO
cik: 0001347242
company_name: LIPELLA PHARMACEUTICALS INC.
filed_at: 2025-05-15T23:59:59+00:00
discovered_at: 2026-05-14T18:02:48.041467+00:00
generated_at: 2026-05-21T04:42:07.497693+00:00
sec_items: ["7.01", "8.01", "9.01"]
event_type: other_material
sentiment: positive
materiality_score: 0.75
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001753926-25-000842
json_url: https://secwatch.observer/filing/0001753926-25-000842.json
markdown_url: https://secwatch.observer/filing/0001753926-25-000842.md
text_url: https://secwatch.observer/filing/0001753926-25-000842.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1347242/000175392625000842/0001753926-25-000842-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1347242/000175392625000842/g084819_8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001753926-25-000842

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.